Understanding how certain enzymes affect the production of the Hepatitis B virus
Official title: Developmental regulation of HBV biosynthesis by Ten-eleven translocation (Tet) methylcytosine dioxygenases
Funded at University of Illinois at Chicago · NIH-11129627 · Data updated 2026-11-12
This study is looking at how certain enzymes in the body affect the Hepatitis B virus and its ability to grow, with the hope of finding new ways to help people manage or even cure their HBV infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | June 9, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $391,196 |
| NIH project number | 5R01AI170785-03 |
| Project ID | NIH-11129627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are chronic carriers of Hepatitis B virus, particularly those experiencing acute liver disease.
✕Less likely to help
Patients who do not have Hepatitis B virus infection or those with other unrelated liver conditions may not benefit from this research.
What this research studies
This research investigates the role of Ten-eleven translocation (Tet) enzymes in the biosynthesis of the Hepatitis B virus (HBV). By using specially developed mouse models, the study aims to understand how these enzymes influence the viral DNA's structure and its ability to replicate. The research focuses on the mechanisms that lead to chronic HBV infections and seeks to identify potential therapeutic targets that could lead to effective treatments. Patients may benefit from insights gained into how to better manage or potentially cure HBV infections.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively eliminate chronic Hepatitis B infections.
How similar studies have gone: Previous research has shown promise in targeting viral biosynthesis mechanisms, suggesting that this approach could lead to significant advancements in HBV treatment.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Mclachlan, Alan — University of Illinois at Chicago
- Study coordinator: Mclachlan, Alan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.